|
Background: Causes of blood cell diseases can range from genetic, as in cancer, to infectious, as in malaria. In all cases, treatments are directed at modulating the survival or differentiation of the affected cell population. Unfortunately, drug and vaccine development are continuously hampered by the absence of good, in vivo models that can mimic the complexity of the human immune system.
Technology: Using a biomarker for cancer stem cells, UC researchers have developed an in vivo stem cell model that allows non-invasive, real-time analysis of human blood cell development. This technology involves the superposition of:
- a human Jak2 mutation that drives blood cell development,
- a bioluminescent vector that can be imaged in vivo and in vitro, and
- a xenogeneic mouse with high level blood cell engraftment.
The ability to engage an intact, human immune system may provide means to (i) test cancer therapeutic agents (ii) select patient populations that may respond to a targeted therapeutic and (iii) develop vaccines to treat malaria and other pathogens that infect red blood cells.
Patents pending
Research Interest: http://cancer.ucsd.edu/summaries/cjamieson.asp
Related Case: SD2007-099, SD2007-241
Publications:
- Jamieson CH, et. al., Chronic versus acute myelogenous leukemia: a question of self-renewal, Cancer Cell 2004 6(6):531-3.
- Jamieson CH, et. al., Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML, N Engl J Med. 2004 351(7):657-67.
- Passegue E, et. al., Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci U S A. 2003 100 Suppl 1:11842-9, Review.
- Traggiai, E. et. al., Development of a human adaptive immune system in cord blood cell- transplanted mice. Science. 2004 304(5667):104-7.
Case No: SD2007-090
Keywords: : in vivo, cancer, xenogeneic, model, malaria, drug resistance, hematopoiesis, leukemic, leukemia, biomarker, Jak, polycythemia vera, differentiation, progenitor, stem cell, CML, real-time, biomarker, small molecule, drug development, screening
Inquiries To: invent@ucsd.edu
|
